Article Text

Download PDFPDF
Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey
  1. Gabriella Ferrandina, MD*,,,
  2. Giulia Amadio, MD,
  3. Ida Paris, MD,
  4. Mariagrazia Distefano, MD,
  5. Eleonora Palluzzi, MD,
  6. Rosa de Vincenzo, MD,,
  7. Caterina Ricci, MD and
  8. Giovanni Scambia, MD,
  1. * Department of Health Sciences and Medicine, University of Molise, Campobasso;
  2. Gynecologic Oncology Unit, Department Obstetrics/Gynecology, Fondazione “Policlinico Universitario A. Gemelli”, Rome; and
  3. Catholic University of Rome, Italy.
  1. Address correspondence and reprint requests to Gabriella Ferrandina, MD, Department of Health Sciences and Medicine, University of Molise, Campobasso Gynecologic Oncology Unit, Fondazione “Policlinico Universitario A. Gemelli,” L.go Agostino Gemelli 8 00168, Rome, Italia. E-mail: gabriella.ferrandina{at}


Background Trabectedin (T) plus pegylated liposomal doxorubicin (PLD) is approved for treatment of platinum-sensitive recurrent ovarian cancer (ROC). Despite the recommendations and guidelines, variations in managing T/PLD administration in routine clinical practice cannot be excluded. We aimed at setting up an Italian survey collecting data about management of T/PLD administration in ROC patients.

Methods We carried out the development of a questionnaire-based survey on routine clinical practice in the management of ROC patients administered T/PLD. The survey registered the physicians’ approach to modification/discontinuation of treatment, type of modifications, reasons why, and so on. The survey was transmitted to medical oncologists and gynecologic oncologists practicing in national centers/institutions.

Results Fifty-eight Italian centers/institutions returned the compiled questionnaire; participants practiced at community cancer centers or hospitals (56.9%), academic institutions (36.2%), and other settings (private clinics, etc) (6.9%). There was no statistically significant difference in the distribution of practice setting according to geographic areas. Most responders were medical oncologists (84.5%) and were members (82.8%) of at least 1 scientific society or cooperative group. Almost 31.5% of responders reported interruption of the whole treatment, mostly because of toxicity (41.2%), followed by patients’ choice (29.4%), or achievement of clinical benefit (23.5%). Dose reduction was referred by 47.4% of responders. Reduction of dose for both drugs was referred by 88.5% of responders, and the extent of dose reduction ranged between 10% and 30%.

Conclusions This survey highlights the gaps in transposing evidence-based or consensus guidelines in the real-world management of T/PLD administration; these findings could be useful in order to focus the attention on specific knowledge and/or experience gaps and plan pertinent educational programs.

  • Management of adverse effect
  • Pegylated liposomal doxorubicin
  • Recurrent ovarian cancer
  • Survey
  • Trabectedin

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.